CVKD vs. ANRO

Last updated Apr 1, 2026

Compare and contrast key facts about Cadrenal Therapeutics Inc. Common Stock (CVKD) and Alto Neuroscience, Inc (ANRO).

Performance

CVKD vs. ANRO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cadrenal Therapeutics Inc. Common Stock (CVKD) and Alto Neuroscience, Inc (ANRO). The values are adjusted to include any dividend payments, if applicable.

CVKD vs. ANRO - Yearly Performance Comparison

	2026 (YTD)	2025	2024
CVKD Cadrenal Therapeutics Inc. Common Stock	-24.48%	-53.21%	-28.44%
ANRO Alto Neuroscience, Inc	26.29%	320.80%	-79.57%

Fundamentals

Market Cap CVKD : $10.21M ANRO : $717.64M
EPS CVKD : -$5.10 ANRO : -$2.20
PB Ratio CVKD : 3.73 ANRO : 4.75
Total Revenue (TTM) CVKD : $0.00 ANRO : $0.00
Gross Profit (TTM) CVKD : -$5.92K ANRO : -$421.00K
EBITDA (TTM) CVKD : -$13.32M ANRO : -$61.63M

Returns By Period

In the year-to-date period, CVKD achieves a -24.48% return, which is significantly lower than ANRO's 26.29% return.

CVKD

• 1D: 20.47%
• 1M: -39.69%
• YTD: -24.48%
• 6M: -62.98%
• 1Y: -70.96%
• 3Y*: -37.68%
• 5Y*: —
• 10Y*: —

ANRO

• 1D: 12.51%
• 1M: 14.17%
• YTD: 26.29%
• 6M: 459.20%
• 1Y: 940.74%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CVKD vs. ANRO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CVKD

CVKD Risk / Return Rank: 7
CVKD Sharpe Ratio Rank: 10
CVKD Sortino Ratio Rank: 9
CVKD Omega Ratio Rank: 10
CVKD Calmar Ratio Rank: 5
CVKD Martin Ratio Rank: 3

ANRO

ANRO Risk / Return Rank: 99
ANRO Sharpe Ratio Rank: 100
ANRO Sortino Ratio Rank: 99
ANRO Omega Ratio Rank: 98
ANRO Calmar Ratio Rank: 100
ANRO Martin Ratio Rank: 100

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CVKD vs. ANRO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cadrenal Therapeutics Inc. Common Stock (CVKD) and Alto Neuroscience, Inc (ANRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CVKD	ANRO	Difference
Sharpe ratio Return per unit of total volatility	-0.74	7.25	-7.99
Sortino ratio Return per unit of downside risk	-1.18	5.65	-6.84
Omega ratio Gain probability vs. loss probability	0.86	1.71	-0.85
Calmar ratio Return relative to maximum drawdown	-0.95	30.09	-31.04
Martin ratio Return relative to average drawdown	-1.81	72.94	-74.76
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CVKD vs. ANRO - Sharpe Ratio Comparison

The current CVKD Sharpe Ratio is -0.74, which is lower than the ANRO Sharpe Ratio of 7.25. The chart below compares the historical Sharpe Ratios of CVKD and ANRO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CVKD	ANRO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.74	7.25	-7.99
Sharpe Ratio (All Time) Calculated using the full available price history	-0.53	0.03	-0.57

Correlation

The correlation between CVKD and ANRO is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CVKD vs. ANRO - Dividend Comparison

Neither CVKD nor ANRO has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CVKD vs. ANRO - Drawdown Comparison

The maximum CVKD drawdown since its inception was -93.12%, roughly equal to the maximum ANRO drawdown of -91.74%. Use the drawdown chart below to compare losses from any high point for CVKD and ANRO.

Drawdown Indicators

	CVKD	ANRO	Difference
Max Drawdown Largest peak-to-trough decline	-93.12%	-91.74%	-1.38%
Max Drawdown (1Y) Largest decline over 1 year	-75.95%	-29.59%	-46.36%
Current Drawdown Current decline from peak	-91.72%	-7.45%	-84.27%
Average Drawdown Average peak-to-trough decline	-78.08%	-56.91%	-21.17%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.89%	12.21%	+27.68%

Volatility

CVKD vs. ANRO - Volatility Comparison

Cadrenal Therapeutics Inc. Common Stock (CVKD) has a higher volatility of 30.09% compared to Alto Neuroscience, Inc (ANRO) at 24.93%. This indicates that CVKD's price experiences larger fluctuations and is considered to be riskier than ANRO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CVKD	ANRO	Difference
Volatility (1M) Calculated over the trailing 1-month period	30.09%	24.93%	+5.16%
Volatility (6M) Calculated over the trailing 6-month period	78.40%	98.02%	-19.62%
Volatility (1Y) Calculated over the trailing 1-year period	95.64%	131.26%	-35.62%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	101.78%	118.76%	-16.98%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	101.78%	118.76%	-16.98%

Financials